The PDGF receptor inhibitor imatinib showed efficacy in COL1A1‐PDGFB‐positive dermatofibrosarcoma protuberans as adjuvant therapy, confirming the importance of the PDGF‐BB autocrine loop in tumour growth.33 This evidence concerns the gene COL1A1 and dermatofibrosarcoma protuberans.